< previous page page_79 next page >

Page 79
4
Managing the Overall Portfolio for Successful Discovery and Development
Rebecca J. Anderson
Boehringer Ingelheim Pharmaceuticals, Inc.
Ridgefield, Connecticut
6fb6ffc4153cdc534470145c4eef46f0.gif
I. Introduction: the Existing Situation
80
6fb6ffc4153cdc534470145c4eef46f0.gif
II. Differences between Research and Development
81
6fb6ffc4153cdc534470145c4eef46f0.gif
III. Monitoring and Controlling R & D Costs
83
6fb6ffc4153cdc534470145c4eef46f0.gif
A. Elements of the Budget
83
6fb6ffc4153cdc534470145c4eef46f0.gif
B. Considerations in Budget Control
84
6fb6ffc4153cdc534470145c4eef46f0.gif
IV. Balance between Research and Development
85
6fb6ffc4153cdc534470145c4eef46f0.gif
V. Factors that Contribute to R & D Costs and Ways to Control them
86
6fb6ffc4153cdc534470145c4eef46f0.gif
A. Effectiveness
86
6fb6ffc4153cdc534470145c4eef46f0.gif
B. Efficiency
88
6fb6ffc4153cdc534470145c4eef46f0.gif
C. Quality
96
6fb6ffc4153cdc534470145c4eef46f0.gif
D. Innovation
97
6fb6ffc4153cdc534470145c4eef46f0.gif
E. Integrity
100
6fb6ffc4153cdc534470145c4eef46f0.gif
VI. The R & D Portfolio
101
6fb6ffc4153cdc534470145c4eef46f0.gif
A. Portfolio Considerations and Complications
101
6fb6ffc4153cdc534470145c4eef46f0.gif
B. Dimensions and Criteria for Portfolio Analysis
103

 
< previous page page_79 next page >